Immunai Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immunai Inc. - overview
Established
2018
Location
New York, NY, US
Primary Industry
Biotechnology
About
Immunai Inc. is a New York-based biotechnology company focused on decoding immunity by mapping the immune system, utilizing advanced techniques and comprehensive data integration to drive therapeutic advancements. Founded in 2018 in New York, US, Immunai Inc. specializes in decoding immunity through its innovative platform.
The company has undergone strategic pivots to enhance its focus on multiomic data integration. The founders include Ansuman Satpathy, Danny Wells, and Luis Voloch, while Noam Solomon serves as CEO. In October 2021, Immunai raised USD 219 million in Series C funding, led by Koch Disruptive Technologies, with participation from notable investors including 8VC and Alexandria Venture Investments, bringing the total amount raised to USD 219 million and the current valuation to USD 1,024. 70 mn.
Immunai's offerings center around its advanced platform for decoding immunity, utilizing high-quality multiomic data from clinical and preclinical samples. Key solutions include Target Discovery for identifying disease-related targets, Preclinical Evaluation for prioritizing drug candidates, and Clinical Trial Optimization for enhancing drug understanding. The company caters to a diverse client base, including leading biopharmaceutical firms and research institutions across North America, Europe, and parts of Asia, focusing on next-generation immune-related therapeutics. Immunai generates revenue through partnerships and collaborations with biopharmaceutical companies and research institutions, offering subscription-based access to its platform and data services.
Clients enter into multi-year agreements for these services, including consultations leveraging Immunai's machine learning expertise. Revenue models are structured around the complexity of services provided, aiming to deliver actionable insights that facilitate drug discovery and development processes. Following its recent funding round in October 2021, Immunai plans to utilize the USD 219 million raised to expand its drug actuary platform for target validation and evaluation. The company aims to launch new products designed to enhance capabilities in immune-related drug discovery.
Additionally, Immunai is targeting expansion in new markets, focusing on increasing its presence in Europe and Asia by 2023.
Current Investors
Viola Group, TLV Partners, Duquesne Family Office
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Healthcare IT
Website
www.immunai.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.